Bayer AG (BSE:BAYN) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


BSE:BAYN Bayer AG BSE:BAYN
76 GF Score
Price lei209.00
GF Value lei139.17
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Bayer AG Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Bayer AG's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BSE:BAYN vs LLY, JNJ, ABBV: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - General subindustry, Bayer AG's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bayer AG Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Bayer AG's Margin of Safety % (DCF Earnings Based) falls into.


BSE:BAYN
76GF Score
Bayer AG BSE:BAYN
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bayer AG (BSE:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of lei209.00 is trading 50.2% above its estimated GF Value™ of lei139.17. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for BSE:BAYN:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: lei139.17 vs. price of lei209.00 (50.2% above fair value)
  • GF Score™: 76/100 with 2 warning signs

No single metric tells the full story. See the BSE:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
76GF Score

Get the complete analysis for BSE:BAYN

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei209.00
Price
lei139.17
GF Value